NDA[removed]S013 Sutent (sunitinib malate) ODAC Briefing Document FDA Briefing Document

First Page		Document Content
Indoles Pfizer Pyrroles Sunitinib Renal cell carcinoma Neuroendocrine tumor Progression-free survival Response Evaluation Criteria in Solid Tumors End point of clinical trials Medicine Medical statistics Organofluorides		NDA[removed]S013 Sutent (sunitinib malate) ODAC Briefing Document FDA Briefing Document Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 237,95 KB Share Document on Facebook

	Appendix N Response Evaluation Criteria in Solid Tumors (RECIST) The Response Evaluation Criteria in Solid Tumors (RECIST) were published in February 2000 by the European Organization for Research and Treatment of Cance DocID: 1q9h6 - View Document
	MayImproving Trial Success by Improving Tumor Assessment Jamal Gasmi, MD, PhD l Vice President & Global Leader Oncology & Hematology Drug Development, ICON Clinical Research James Conklin, MD, MS l Senior Vice Pre DocID: 1pCHm - View Document
	Clinical Trial Template Instructions: This template has been created to assist in the development of investigator-initiated interventional clinical trials. Please note that it has two parts. The objective of Part 1 is DocID: 1pCAL - View Document
	High complete and partial response rate in a phase Ib/II pilot trial with albumin-bound paclitaxel and gemcitabine plus cisplatin in patients with advanced pancreatic cancer Jameson GS1, Borazanci E1, Poplin E2, Barrett DocID: 1osIl - View Document
	Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study A Sekulic,1 MR Migden,2 AE Oro,3 L Dirix,4 K Lewis,5 JD Hainsworth,6 DocID: 1gamh - View Document